Park, Sei-Kyoung published the artcileInhibition of A¦Â42 oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs, Application of N1,N2-Dibenzylethane-1,2-diamine, the publication is Microbial Cell (2016), 3(2), 53-64, database is CAplus and MEDLINE.
The formation of small A¦Â42 oligomers has been implicated as a toxic species in Alzheimer disease (AD). In strong support of this hypothesis we found that overexpression of Yap1802, the yeast ortholog of the human AD risk factor, phosphatidylinositol binding clathrin assembly protein (PICALM), reduced oligomerization of A¦Â42 fused to a reporter in yeast. Thus we used the A¦Â42-reporter system to identify drugs that could be developed into therapies that prevent or arrest AD. From a screen of 1,200 FDA approved drugs and drug-like small compounds we identified 7 drugs that reduce A¦Â42 oligomerization in yeast: 3 antipsychotics (bromperidol, haloperidol and azaperone), 2 anesthetics (pramoxine HCl and dyclonine HCl), tamoxifen citrate, and minocycline HCl. Also, all 7 drugs caused A¦Â42 to be less toxic to PC12 cells and to relieve toxicity of another yeast AD model in which A¦Â42 aggregates targeted to the secretory pathway are toxic. Our results identify drugs that inhibit A¦Â42 oligomers from forming in yeast. It remains to be determined if these drugs inhibit A¦Â42 oligomerization in mammals and could be developed as a therapeutic treatment for AD.
Microbial Cell published new progress about 140-28-3. 140-28-3 belongs to catalysis-chemistry, auxiliary class Benzenes, name is N1,N2-Dibenzylethane-1,2-diamine, and the molecular formula is C16H20N2, Application of N1,N2-Dibenzylethane-1,2-diamine.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia